(AOF) – The positive results of the clinical trial devoted to Dupixent (dupilumab) in the treatment of atopic dermatitis of the hands and feet, moderate to severe, uncontrolled in adults and adolescents were presented on Saturday . This trial, the first to assess the benefit of a biological drug in this difficult-to-treat population, met its primary and secondary endpoints. These findings were presented during a topical session at the 2023 Congress of the American Academy of Dermatology (AAD).
Dr. Eric L. Simpson, Frances J. Storrs Chair in Medical Dermatology at Oregon Health and Science University and principal investigator of the trial, said: “Although the efficacy and safety profile of Dupixent in the treatment of atopic dermatitis is well established, these positive results are the first to illustrate the effect of this drug on specific and also essential parts of the body.”
At week 16, patients treated with Dupixent showed the following results in particular. Clear or almost clear skin was seen on the hands and feet for 40% of patients compared to 17% of placebo-treated patients (p≤0.01) – the study’s primary endpoint.
There was also a clinically significant reduction in itching on the hands and feet for 52% of patients, compared to 14% for patients treated with placebo (p<0.0001) –="" the="" main=" " criterion="" of evaluation="" secondary.
There were also significant improvements in hand and foot pain scores, sleep quality and quality of life in relation to eczema.
The potential use of Dupixent for the treatment of chronic spontaneous urticaria is the subject of a clinical development program and no regulatory body has yet fully evaluated its safety and efficacy profiles in this indication.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial exploitation or not, creation of a hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION. FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not in any way guarantee the absence of error and defects, even hidden ones, nor the exhaustive nature or the lack of conformity for any use whatsoever of this data and of OPTION FINANCE SAS or one of its contributors, and cannot be held responsible for any delays or interruptions that may affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember on the financial markets.
